OBJECTIVETo determine densities of mineral drugs and their calcined products by using sealing wax densimetry, and to establish the testing method of crispness for calcined traditional Chinese medicine.

METHODTaking density as detection indicator, the accuracies of mineral drugs and their calcined products were investigated by sealing wax densimetry compared with direct densimetry, and the method of density determination was optimized.

RESULTThe density values measured by two methods investigated above were significantly different (P < 0.01), the density values of Pyritum, Haematitum, calcined Pyritum and calcined Haematitum measured by direct densimetry were increased 1.66%, 9.43%, 96.72% and 9.02%, respectively compared with that measured by sealing wax densimetry.

CONCLUSIONSealing wax densimetry is suitable for the density determination of mineral drugs and their calcined products with its high accuracy, whereas direct densimetry'is not suitable for the density determination of mineral drugs and their calcined products.

Densitometry ; methods ; Drugs, Chinese Herbal ; chemistry ; Waxes

BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) is intimately related to insulin resistance and ranges from a benign course to liver fibrosis and cirrhosis. NAFLD management mainly involves dietary modification and weight loss. Although no fully successful pharmacological intervention is available, alternative therapies to treat NAFLD have shown promising results. Experimental studies have shown that D-002, a mixture of beeswax alcohols with antioxidant effects, is hepatoprotective. The aim of this study was to investigate the efficacy and safety of D-002 in patients with NALFD. METHODS: Fifty patients with NAFLD were randomized to receive a placebo or D-002 (100 mg/day) for 24 weeks. The primary endpoint was a significant ultrasonography-detected reduction of liver fat infiltration versus a placebo. Secondary endpoints were decreases in the homeostatic model assessment (HOMA) index, insulin levels, serum liver enzymes, increases in plasma total antioxidant status (TAS) and improved clinical symptoms versus the placebo recipients. RESULTS: At randomization, all indicators were comparable in both groups. At study completion, seven (28.0%) D-002-patients, but none of the placebo recipients, exhibited a normal liver echo pattern on ultrasonography (p < 0.01). Also, D-002 significantly reduced (p < 0.01 vs. baseline and placebo) the HOMA index and insulin levels and increased the TAS, but did not affect other parameters. The proportion of D-002-patients (12/25, 48.0%) showing symptom improvement was higher (p < 0.001) than that of the placebo group (1/25, 4.0%). The treatment was safe and well tolerated. Three patients in each group withdrew from the study. CONCLUSIONS: D-002 (100 mg/day) improved ultrasonographic findings, indicators of insulin resistance, plasma TAS and clinical evolution on NAFLD patients. Further studies, however, are needed to confirm these results.
Adult ; Aged ; Antioxidants/adverse effects/isolation & purification/*therapeutic use ; Biological Markers/blood ; Blood Glucose/metabolism ; Cuba ; Double-Blind Method ; Enzymes/blood ; Fatty Alcohols/adverse effects/isolation & purification/*therapeutic use ; Fatty Liver/blood/*drug therapy/ultrasonography ; Female ; Humans ; Insulin/blood ; Lipids/blood ; Liver/*drug effects/enzymology/ultrasonography ; Male ; Middle Aged ; Prospective Studies ; Time Factors ; Treatment Outcome ; Waxes/*chemistry